Transfer mechanism of temoporfin between liposomal membranes

Hefesha, Hossam; Loew, Stephan; Liu, Xiangli; May, Sylvio; Fahr, Alfred

doi:10.1016/j.jconrel.2010.09.021

Cited by 42 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug transfer was also studied to small unilamellar liposomes as lipophilic components. Acceptor and donor particles were separated by an ion exchange column technique in this case [10]. Another approach focused on the incorporation of lipophilic acceptor nanoparticles into Ca-alginate microparticles [11].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Drug release studies from lipid nanoparticles in physiological media by a new DSC method

Roese

Bunjes

2017

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

Drug release studies from lipid nanoparticles in physiological media by a new DSC method

Roese

Bunjes

2017

Journal of Controlled Release

View full text Add to dashboard Cite

“…Experimental investigations of the transfer of temoporfin between two different types of liposomes (i.e., from donor liposomes to acceptor liposomes) have recently been carried out using a mini ion exchange column technique [13]. The column separates donor from acceptor liposomes and thus allows to monitor the time dependence of the drug transfer.…”

Section: Introductionmentioning

confidence: 99%

“…In some cases, both mechanisms were suggested to contribute to the transport of lipids between vesicles [18] and to the transport of lipophilic drugs from oil-in-water emulsions to cells [19] and from plasma proteins to lipid vesicles [20]. In our preceding experimental work, where we have investigated the kinetics of temoporfin transport from donor to acceptor liposomes [13], we found that above a certain concentration (corresponding to a liposome-to-liposome distance of about 200 nm for our specific system) the transfer was dominated by collisions; for smaller concentrations transport through diffusion was prevalent.…”

Section: Introductionmentioning

confidence: 99%

Modeling the Release Kinetics of Poorly Water-Soluble Drug Molecules from Liposomal Nanocarriers

Loew

Fahr

May

2011

Journal of Drug Delivery

Self Cite

View full text Add to dashboard Cite

Liposomes are frequently used as pharmaceutical nanocarriers to deliver poorly water-soluble drugs such as temoporfin, cyclosporine A, amphotericin B, and paclitaxel to their target site. Optimal drug delivery depends on understanding the release kinetics of the drug molecules from the host liposomes during the journey to the target site and at the target site. Transfer of drugs in model systems consisting of donor liposomes and acceptor liposomes is known from experimental work to typically exhibit a first-order kinetics with a simple exponential behavior. In some cases, a fast component in the initial transfer is present, in other cases the transfer is sigmoidal. We present and analyze a theoretical model for the transfer that accounts for two physical mechanisms, collisions between liposomes and diffusion of the drug molecules through the aqueous phase. Starting with the detailed distribution of drug molecules among the individual liposomes, we specify the conditions that lead to an apparent first-order kinetic behavior. We also discuss possible implications on the transfer kinetics of (1) high drug loading of donor liposomes, (2) attractive interactions between drug molecules within the liposomes, and (3) slow transfer of drugs between the inner and outer leaflets of the liposomes.

show abstract

“…Thus, additions of hydrophilic excipients were found to adversely affect the stability by promoting the transfer in aqueous phase followed by rapid precipitation. DTX can be transferred to other liposomes by collision between the liposomes or by passive diffusion through aqueous phase [29,30]. Based on this, we hypothesized that addition of blank liposomes might be helpful in inhibiting DTX precipitation.…”

Section: Discussionmentioning

confidence: 99%

Tumor Stromal Disrupting Agent Enhances the Anticancer Efficacy of Docetaxel Loaded PEGylated Liposomes in Lung Cancer

Patel

Doddapaneni

Chowdhury

et al. 2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: Therapeutic efficacy of anticancer nanomedicine is compromised by tumor stromal barriers. The present study deals with the development of docetaxel loaded PEGylated liposomes (DTXPL) and to investigate the effect of tumor stroma disrupting agent, telmisartan, on anticancer efficacy of DTXPL. Methods: DTXPL was prepared using proprietary modified hydration method. Effect of oral telmisartan treatment on tumor uptake of coumarin-6 liposomes and anticancer efficacy of DTXPL was evaluated in orthotopic xenograft lung tumor bearing mice. Results: DTXPL (105.7 ± 3.8 nm) showed very high physical stability, negligible hemolysis, 428% enhancement in bioavailability with significantly higher intratumoral uptake. Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. Conclusion: Combination of DTXPL with telmisartan could significantly enhance clinical outcome in lung cancer. Lung cancer is by far the most common cause of cancer related mortality in both men and women. Non-small-cell lung cancer (NSCLC) accounts for 87% of total cases of lung cancer with overall 5-year survival rate less than 18.2% [1,2]. Depending on the stage of lung cancer and condition of patients, the chemotherapeutic regimen for lung cancer includes following drugs: Cisplatin/carboplatin or paclitaxel/docetaxel, etoposide, vinorelbine, erlotinib or other tyrosine kinase inhibitors, gemcitabine and pemetrexed. Despite recent advances in diagnosis and treatment, the clinical outcome amongst NSCLC patients is still not impressive. Docetaxel (DTX) is one the most widely used for drug for the treatment of various types of solid tumor including ovarian, breast, lung and head/neck cancers. Docetaxel has extremely poor water solubility and rapid precipitation tendency, which necessitates very high concentration of ethanol and surfactant for its intravenous injection. Tween 80 in Taxotere ® formulation is responsible for severe life threatening hypersensitivity and peripheral neuropathy [3,4]. A safer formulation to enhance patient compliance and therapeutic efficacy of DTX is always in demand. As a result, current research is mainly focused on developing nanomedicinal formulation such as liposomes, polymeric micelles, albumin nanoparticles, polymer drug conjugates, etc. Liposomes are the most versatile nanocarrier with superior biocompatibility and large scale manufacturing feasibility compared to other types of nanocarrier. Abraxane ® ,

show abstract

Transfer mechanism of temoporfin between liposomal membranes

Cited by 42 publications

References 30 publications

Drug release studies from lipid nanoparticles in physiological media by a new DSC method

Drug release studies from lipid nanoparticles in physiological media by a new DSC method

Modeling the Release Kinetics of Poorly Water-Soluble Drug Molecules from Liposomal Nanocarriers

Tumor Stromal Disrupting Agent Enhances the Anticancer Efficacy of Docetaxel Loaded PEGylated Liposomes in Lung Cancer

Contact Info

Product

Resources

About